Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Three additional approvals for Rilutek

Nov. 25, 1996

Marinol promising for geriatric AD

Nov. 25, 1996

SNX-111 effective in chronic intractable pain

Nov. 25, 1996

Maxi-K channel modulators from Bristol-Myers Squibb

Nov. 25, 1996

Lilly claims structurally novel NK1 antagonists

Nov. 25, 1996

NeoTherapeutics' lead small molecule advances toward clinical trials in AD

Nov. 22, 1996

Guilford's orally active neuroimmunophilin highly effective in animal models of Parkinson's disease

Nov. 22, 1996

Lamotrigine now available in France

Nov. 22, 1996

Antiparkinsonian skin patch enters pivotal phase II trial

Nov. 22, 1996

Approval recommended for Elan's gel formulation of diazepam

Nov. 21, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.